Skip to content
  • Clinical Studies
  • Pharma GMP
  • Pharma Tips
  • Stability Studies
  • Pharma Books
  • Schedule M

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • SOP – Blog Post
  • Toggle search form

BA-BE Studies: SOP for Labelling of Biological Samples – V 2.0

Posted on By

BA-BE Studies: SOP for Labelling of Biological Samples – V 2.0

Standard Operating Procedure for Labelling of Biological Samples in BA/BE Studies

Department BA-BE Studies
SOP No. SOP/BA-BE/073/2025
Supersedes SOP/BA-BE/073/2022
Page No. Page 1 of 9
Issue Date 17/04/2025
Effective Date 20/04/2025
Review Date 17/04/2026

1. Purpose

To provide a standardized procedure for labelling biological samples, including blood and plasma, collected during Bioavailability/Bioequivalence (BA/BE) studies to ensure traceability, prevent mix-ups, and support regulatory compliance.

2. Scope

This SOP is applicable to all clinical and laboratory personnel responsible for primary and secondary labelling of biological samples (whole blood, plasma, serum) in BA/BE studies conducted at the clinical site or affiliated laboratories.

3. Responsibilities

  • Phlebotomist: Performs initial labelling of collection tubes immediately after sample withdrawal.
  • Lab Technician: Applies secondary labels on plasma aliquots post-centrifugation.
  • CRC (Clinical Research Coordinator): Cross-verifies label content and ensures accuracy against subject ID and timepoint schedule.
See also  BA-BE Studies: SOP for Selecting Bioequivalence Study Design (Crossover, Parallel, etc.) - V 2.0

4. Accountability

The Principal Investigator is accountable for ensuring proper labelling procedures are followed and any discrepancies are addressed prior to analysis or storage.

5. Procedure

5.1 Primary Labelling (Pre-Centrifugation)

  1. Label blood collection tubes before sample collection or immediately after using indelible, waterproof markers or pre-printed barcode labels.
  2. Each label must include:
    • Subject ID (e.g., VOL-073)
    • Period Number (e.g., P1, P2)
    • Time Point (e.g., 2h)
    • Date of Collection
  3. Example: VOL-073/P1/2h/17-04-2025
  4. Record this information in Annexure-1: Sample Label Verification Log.

5.2 Secondary Labelling (Post-Centrifugation)

  1. Transfer plasma to labelled cryovials using separate sterile pipettes for each subject.
  2. Secondary label must include:
    • Same details as primary label
    • Aliquot number (if applicable)
    • Sample type (e.g., Plasma)
  3. Example: VOL-073/P1/2h/A1/Plasma
  4. Verify label before storing sample in -20°C or -70°C freezer as per protocol.
See also  BA-BE Studies: SOP for Setting Up eTMF (Electronic Trial Master File) - V 2.0

5.3 Barcode Labelling (If Applicable)

  1. Use validated barcode software integrated with study database.
  2. Scan barcode post-labelling and log confirmation in Annexure-2: Barcode Verification Log.

5.4 Cross-Verification of Labels

  1. CRC or QA personnel must:
    • Verify 100% of labels for accuracy and legibility
    • Confirm subject ID, timepoint, and sample type
  2. Document discrepancies and corrections in Annexure-3: Label Discrepancy Log.

5.5 Label Integrity and Storage

  1. Ensure labels are:
    • Non-smudging, waterproof, and resistant to freezing temperatures
    • Securely affixed and legible after centrifugation or storage

5.6 Deviation Management

  1. Label errors must be immediately corrected and signed off by the CRC and PI.
  2. Record in Annexure-3 and notify the QA unit for impact assessment.

6. Abbreviations

  • BA: Bioavailability
  • BE: Bioequivalence
  • CRC: Clinical Research Coordinator
  • PI: Principal Investigator

7. Documents

  1. Sample Label Verification Log – Annexure-1
  2. Barcode Verification Log (if applicable) – Annexure-2
  3. Label Discrepancy Log – Annexure-3
See also  BA-BE Studies: SOP for IMP Destruction or Return Process - V 2.0

8. References

  • ICH E6(R2) – Good Clinical Practice
  • US FDA BA/BE Guidance
  • Study Protocol and Lab Manual

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Sample Label Verification Log

Subject ID Timepoint Label Checked By Date Remarks
VOL-073 2h Sunita Reddy 17/04/2025 Correct

Annexure-2: Barcode Verification Log

Subject ID Label Code Scan Verified By Date Status
VOL-073 BAR-073-P1-2H R. Pawar 17/04/2025 Verified

Annexure-3: Label Discrepancy Log

Subject ID Error Noted Correction Corrected By Reviewed By
VOL-073X Timepoint missing Added 2h Nisha Verma Dr. Arvind Shah

Revision History:

Revision Date Revision No. Details Reason Approved By
12/01/2022 1.0 Initial release Process standardization QA Head
17/04/2025 2.0 Added barcode process and discrepancy log Audit compliance QA Head
BA-BE Studies V 2.0 Tags:Absolute bioavailability, AUC (area under the curve), Bioavailability, Bioequivalence, Bioequivalence criteria, CDSCO bioequivalence norms, Clinical trial registration, Cmax (maximum concentration), Confidence interval %, Crossover study design, EMA bioequivalence requirements, Ethics committee approval, FDA bioequivalence guidelines, Generic drug approval, Good Clinical Practice (GCP), Good Laboratory Practice (GLP), Half-life (t½), ICH E(R) compliance, In vitro dissolution, In vivo studies, Informed consent process, Pharmacodynamics, Pharmacokinetics, Randomized controlled trial, Regulatory submission process, Relative bioavailability, Sample size calculation, Therapeutic equivalence, Tmax (time to maximum concentration), Washout period

Post navigation

Previous Post: API Manufacturing: SOP for Monitoring of Solvent Recovery Efficiency – V 2.0
Next Post: Tablets: SOP for Cleaning of Packing Machines Between Batches – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version